After nearly 60 years, Mylan makes way for Viatris

PITTSBURGH — After nearly 60 years as a West Virginia and Pennsylvania pharmaceutical company, Mylan NV has transformed into Viatris (Nasdaq: VTRS), the global drug manufacturer formed with the merger of Mylan and the Upjohn division of Pfizer Inc.

The merger, announced in late July 2019, took effect Monday. The new company will trade on Nasdaq with the ticker symbol VTRS, and Mylan (Nasdaq: MYL) will no longer trade. Viatris' management team is based in Pittsburgh, and the company is incorporated in Delaware.

Viatris is headquartered in the United States and will retain its Canonsburg facility as one of its three global centers, with the other two in Shanghai and Hyderabad, India. It also has a big manufacturing plant and research and development center in Morgantown, West Virginia. There are 45,000 employees in the combined company, but it said in a statement Monday that it was beginning a restructuring program that would save $1 billion.

Read more from our news partners at the Pittsburgh Business Times.

Chief Meteorologist Stephen Cropper’s Winter Weather Forecast

Pittsburgh Business Times